Deletion of the braun lipoprotein-encoding gene and altering the function of lipopolysaccharide attenuate the plague bacterium

Infection and Immunity

Volumn 81, Issue 3, 2013, Pages 815-828

  Sha, Jian ^a,b   Kirtley, Michelle L ^a   van Lier, Christina J ^a   Wang, Shaofei ^a   Erova, Tatiana E ^a   Kozlova, Elena V ^a   Cao, Anthony ^a   Cong, Yingzi ^a,b   Fitts, Eric C ^a   Rosenzweig, Jason A ^c   Chopra, Ashok K ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c TEXAS SOUTHERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; BACTERIUM LIPOPOLYSACCHARIDE; BRAUN LIPOPROTEIN; LAURIC ACID; LIPID A; PEPTIDOGLYCAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DELETION MUTANT; IMMUNOGENICITY; MACROPHAGE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLAGUE; PRIORITY JOURNAL; SURVIVAL;

ANIMALS; ANTI-BACTERIAL AGENTS; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, BACTERIAL; GENTAMICINS; LIPOPOLYSACCHARIDES; LIPOPROTEINS; MICE; MICROBIAL SENSITIVITY TESTS; PLAGUE; RATS; VIRULENCE; YERSINIA PESTIS;

EID: 84874669741     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01067-12     Document Type: Article

References (64)

1. Dennis DT, Chu MC. 2003. A major new test for plague. Lancet 361:191-192.
2. Chanteau S, Rahalison L, Ralafiarisoa L, Foulon J, Ratsitorahina M, Ratsifasoamanana L, Carniel E, Nato F. 2003. Development and testing of a rapid diagnostic test for bubonic and pneumonic plague. Lancet 361: 211-216.
3. Ratsitorahina M, Chanteau S, Rahalison L, Ratsifasoamanana L, Boisier P. 2000. Epidemiological and diagnostic aspects of the outbreak of pneumonic plague in Madagascar. Lancet 355:111-113.
4. Liu T, Agar SL, Sha J, Chopra AK. 2010. Deletion of Braun lipoprotein gene (lpp) attenuates Yersinia pestis KIM/D27 strain: role of Lpp in modulating host immune response, NF-kappaB activation and cell death. Microb. Pathog. 48:42-52.
5. Feodorova VA, Corbel MJ. 2009. Prospects for new plague vaccines. Expert Rev. Vaccines 8:1721-1738.
6. Glauser MP, Zanetti G, Baumgartner JD, Cohen J. 1991. Septic shock: pathogenesis. Lancet 338:732-736.
7. Braun V, Hantke K. 1974. Biochemistry of bacterial cell envelopes. Annu. Rev. Biochem. 43:89-121.
8. Hayashi S, Wu HC. 1990. Lipoproteins in bacteria. J. Bioenerg. Biomembr. 22:451-471.
9. Rebeil R, Ernst RK, Jarrett CO, Adams KN, Miller SI, Hinnebusch BJ. 2006. Characterization of late acyltransferase genes of Yersinia pestis and their role in temperature-dependent lipid A variation. J. Bacteriol. 188: 1381-1388.
10. Nikaido H. 2003. Molecular basis of bacterial outer membrane permeability revisited. Microbiol. Mol. Biol. Rev. 67:593-656.
11. Somerville JE, Jr, Cassiano L, Bainbridge B, Cunningham MD, Darveau RP. 1996. A novel Escherichia coli lipid A mutant that produces an antiinflammatory lipopolysaccharide. J. Clin. Invest. 97:359-365.
12. Clementz T, Bednarski JJ, Raetz CR. 1996. Function of the htrB high temperature requirement gene of Escherichia coli in the acylation of lipid A: HtrB catalyzed incorporation of laurate. J. Biol. Chem. 271:12095-12102.
13. Clementz T, Zhou Z, Raetz CR. 1997. Function of the Escherichia coli msbB gene, a multicopy suppressor of htrB knockouts, in the acylation of lipid A. Acylation by MsbB follows laurate incorporation by HtrB. J. Biol. Chem. 272:10353-10360.
14. Anisimov AP, Shaikhutdinova RZ, Pan'kina LN, Feodorova VA, Savostina EP, Bystrova OV, Lindner B, Mokrievich AN, Bakhteeva IV, Titareva GM, Dentovskaya SV, Kocharova NA, Senchenkova SN, Holst O, Devdariani ZL, Popov YA, Pier GB, Knirel YA. 2007. Effect of deletion of the lpxM gene on virulence and vaccine potential of Yersinia pestis in mice. J. Med. Microbiol. 56:443-453.
15. Oyston PC, Prior JL, Kiljunen S, Skurnik M, Hill J, Titball RW. 2003. Expression of heterologous O-antigen in Yersinia pestis KIM does not affect virulence by the intravenous route. J. Med. Microbiol. 52:289-294.
16. Perez-Gutierrez C, Llobet E, Llompart CM, Reines M, Bengoechea JA. 2010. Role of lipid A acylation in Yersinia enterocolitica virulence. Infect. Immun. 78:2768-2781.
17. Knirel YA, Lindner B, Vinogradov EV, Kocharova NA, Senchenkova SN, Shaikhutdinova RZ, Dentovskaya SV, Fursova NK, Bakhteeva IV, Titareva GM, Balakhonov SV, Holst O, Gremyakova TA, Pier GB, Anisimov AP. 2005. Temperature-dependent variations and intraspecies diversity of the structure of the lipopolysaccharide of Yersinia pestis. Biochemistry 44:1731-1743.
18. Rebeil R, Ernst RK, Gowen BB, Miller SI, Hinnebusch BJ. 2004. Variation in lipid A structure in the pathogenic yersiniae. Mol. Microbiol. 52:1363-1373.
19. Kawahara K, Tsukano H, Watanabe H, Lindner B, Matsuura M. 2002. Modification of the structure and activity of lipid A in Yersinia pestis lipopolysaccharide by growth temperature. Infect. Immun. 70:4092-4098.
20. Montminy SW, Khan N, McGrath S, Walkowicz MJ, Sharp F, Conlon JE, Fukase K, Kusumoto S, Sweet C, Miyake K, Akira S, Cotter RJ, Goguen JD, Lien E. 2006. Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response. Nat. Immunol. 7:1066-1073.
21. Parkhill J, Wren BW, Thomson NR, Titball RW, Holden MT, Prentice MB, Sebaihia M, James KD, Churcher C, Mungall KL, Baker S, Basham D, Bentley SD, Brooks K, Cerdeno-Tarraga AM, Chillingworth T, Cronin A, Davies RM, Davis P, Dougan G, Feltwell T, Hamlin N, Holroyd S, Jagels K, Karlyshev AV, Leather S, Moule S, Oyston PC, Quail M, Rutherford K, Simmonds M, Skelton J, Stevens K, Whitehead S, Barrell BG. 2001. Genome sequence of Yersinia pestis, the causative agent of plague. Nature 413:523-527.
22. +-response plasmid pCD1 of Yersinia pestis KIM5. Infect. Immun. 66:4611-4623.
23. Deng W, Burland V, Plunkett G, 3rd, Boutin A, Mayhew GF, Liss P, Perna NT, Rose DJ, Mau B, Zhou S, Schwartz DC, Fetherston JD, Lindler LE, Brubaker RR, Plano GV, Straley SC, McDonough KA, Nilles ML, Matson JS, Blattner FR, Perry RD. 2002. Genome sequence of Yersinia pestis KIM. J. Bacteriol. 184:4601-4611.
24. Bashir A, Banday MZ, Haq E. 2011. Lipopolysaccharide, mediator of sepsis enigma: recognition and signaling. Int. J. Biochem. Res. Rev. 1:1-13.
25. Pernerstorfer T, Stohlawetz P, Hollenstein U, Dzirlo L, Eichler HG, Kapiotis S, Jilma B, Speiser W. 1999. Endotoxin-induced activation of the coagulation cascade in humans: effect of acetylsalicylic acid and acetaminophen. Arterioscler. Thromb. Vasc. Biol. 19:2517-2523.
26. Jacob A, Hensley LK, Safratowich BD, Quigg RJ, Alexander JJ. 2007. The role of the complement cascade in endotoxin-induced septic encephalopathy. Lab. Invest. 87:1186-1194.
27. Neilsen PO, Zimmerman GA, McIntyre TM. 2001. Escherichia coli Braun lipoprotein induces a lipopolysaccharide-like endotoxic response from primary human endothelial cells. J. Immunol. 167:5231-5239.
28. Zhang H, Peterson JW, Niesel DW, Klimpel GR. 1997. Bacterial lipoprotein and lipopolysaccharide act synergistically to induce lethal shock and proinflammatory cytokine production. J. Immunol. 159:4868-4878.
29. Aliprantis AO, Yang RB, Mark MR, Suggett S, Devaux B, Radolf JD, Klimpel GR, Godowski P, Zychlinsky A. 1999. Cell activation and apoptosis by bacterial lipoproteins through Toll-like receptor-2. Science 285: 736-739.
30. Miyake K. 2004. Innate recognition of lipopolysaccharide by Toll-like receptor 4-MD-2. Trends Microbiol. 12:186-192.
31. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M. 1999. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp. Med. 189:1777-1782.
32. Raetz CR, Whitfield C. 2002. Lipopolysaccharide endotoxins. Annu. Rev. Biochem. 71:635-700.
33. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085-2088.
34. Lien E, Means TK, Heine H, Yoshimura A, Kusumoto S, Fukase K, Fenton MJ, Oikawa M, Qureshi N, Monks B, Finberg RW, Ingalls RR, Golenbock DT. 2000. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J. Clin. Invest. 105:497-504.
35. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda K, Akira S. 1999. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J. Immunol. 162:3749-3752.
36. Rosenzweig JA, Jejelowo O, Sha J, Erova TE, Brackman SM, Kirtley ML, van Lier CJ, Chopra AK. 2011. Progress on plague vaccine development. Appl. Microbiol. Biotechnol. 91:265-286.
37. Naumov AV, Ledvanov MY, Drozdov IG. 1992. Plague immunology. Russian Research Anti-Plague Institute, Saratov, Russia.
38. Titball RW, Williamson ED. 2001. Vaccination against bubonic and pneumonic plague. Vaccine 19:4175-4184.
39. Feodorova VA, Pan'kina LN, Savostina EP, Kuznetsov OS, Konnov NP, Sayapina LV, Dentovskaya SV, Shaikhutdinova RZ, Ageev SA, Lindner B, Kondakova AN, Bystrova OV, Kocharova NA, Senchenkova SN, Holst O, Pier GB, Knirel YA, Anisimov AP, Motin VL. 2009. Pleiotropic effects of the lpxM mutation in Yersinia pestis resulting in modification of the biosynthesis of major immunoreactive antigens. Vaccine 27:2240-2250.
40. Szaba FM, Kummer LW, Wilhelm LB, Lin JS, Parent MA, Montminy-Paquette SW, Lien E, Johnson LL, Smiley ST. 2009. D27-pLpxL, an avirulent strain of Yersinia pestis, primes T cells that protect against pneumonic plague. Infect. Immun. 77:4295-4304.
41. Sun W, Six D, Kuang X, Roland KL, Raetz CR, Curtiss R, 3rd. 2011. A live attenuated strain of Yersinia pestis KIM as a vaccine against plague. Vaccine 29:2986-2998.
42. Loppnow H, Brade H, Durrbaum I, Dinarello CA, Kusumoto S, Rietschel ET, Flad HD. 1989. IL-1 induction-capacity of defined lipopolysaccharide partial structures. J. Immunol. 142:3229-3238.
43. Golenbock DT, Hampton RY, Qureshi N, Takayama K, Raetz CR. 1991. Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes. J. Biol. Chem. 266:19490-19498.
44. Sha J, Agar SL, Baze WB, Olano JP, Fadl AA, Erova TE, Wang S, Foltz SM, Suarez G, Motin VL, Chauhan S, Klimpel GR, Peterson JW, Chopra AK. 2008. Braun lipoprotein (Lpp) contributes to virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague. Infect. Immun. 76:1390-1409.
45. Edwards RA, Keller LH, Schifferli DM. 1998. Improved allelic exchange vectors and their use to analyze 987P fimbria gene expression. Gene 207: 149-157.
46. Sha J, Endsley JJ, Kirtley ML, Foltz SM, Huante MB, Erova TE, Kozlova EV, Popov VL, Yeager LA, Zudina IV, Motin VL, Peterson JW, DeBord KL, Chopra AK. 2011. Characterization of an F1 deletion mutant of Yersinia pestis CO92, pathogenic role of F1 antigen in bubonic and pneumonic plague, and evaluation of sensitivity and specificity of F1 antigen capture-based dipsticks. J. Clin. Microbiol. 49:1708-1715.
47. Fadl AA, Sha J, Klimpel GR, Olano JP, Galindo CL, Chopra AK. 2005. Attenuation of Salmonella enterica serovar Typhimurium by altering biological functions of murein lipoprotein and lipopolysaccharide. Infect. Immun. 73:8433-8436.
48. Fadl AA, Sha J, Klimpel GR, Olano JP, Niesel DW, Chopra AK. 2005. Murein lipoprotein is a critical outer membrane component involved in Salmonella enterica serovar Typhimurium systemic infection. Infect. Immun. 73:1081-1096.
49. Sha J, Fadl AA, Klimpel GR, Niesel DW, Popov VL, Chopra AK. 2004. The two murein lipoproteins of Salmonella enterica serovar Typhimurium contribute to the virulence of the organism. Infect. Immun. 72:3987-4003.
50. Bartra SS, Styer KL, O'Bryant DM, Nilles ML, Hinnebusch BJ, Aballay A, Plano GV. 2008. Resistance of Yersinia pestis to complementdependent killing is mediated by the Ail outer membrane protein. Infect. Immun. 76:612-622.
51. Peterson JW, Comer JE, Baze WB, Noffsinger DM, Wenglikowski A, Walberg KG, Hardcastle J, Pawlik J, Bush K, Taormina J, Moen S, Thomas J, Chatuev BM, Sower L, Chopra AK, Stanberry LR, Sawada R, Scholz WW, Sircar J. 2007. Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model. Infect. Immun. 75:3414-3424.
52. Peterson JW, Comer JE, Noffsinger DM, Wenglikowski A, Walberg KG, Chatuev BM, Chopra AK, Stanberry LR, Kang AS, Scholz WW, Sircar J. 2006. Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax. Infect. Immun. 74:1016-1024.
53. Agar SL, Sha J, Foltz SM, Erova TE, Walberg KG, Baze WB, Suarez G, Peterson JW, Chopra AK. 2009. Characterization of the rat pneumonic plague model: infection kinetics following aerosolization of Yersinia pestis CO92. Microbes Infect. 11:205-214.
54. Ranallo RT, Kaminski RW, George T, Kordis AA, Chen Q, Szabo K, Venkatesan MM. 2010. Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants. Infect. Immun. 78: 400-412.
55. Liu T, Konig R, Sha J, Agar SL, Tseng CT, Klimpel GR, Chopra AK. 2008. Immunological responses against Salmonella enterica serovar Typhimurium Braun lipoprotein and lipid A mutant strains in Swiss-Webster mice: potential use as live-attenuated vaccines. Microb. Pathog. 44:224-237.
56. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry RM, Topalian SL, Yang JC, Stock F, Freezer LJ, Morton KE, Seipp C, Haworth L, Mavroukakis S, White D, MacDonald S, Mao J, Sznol M, Rosenberg SA. 2002. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J. Clin. Oncol. 20:142-152.
57. Feodorova VA, Pan'kina LN, Savostina EP, Sayapina LV, Motin VL, Dentovskaya SV, Shaikhutdinova RZ, Ivanov SA, Lindner B, Kondakova AN, Bystrova OV, Kocharova NA, Senchenkova SN, Holst O, Pier GB, Knirel YA, Anisimov AP. 2007. A Yersinia pestis lpxM-mutant live vaccine induces enhanced immunity against bubonic plague in mice and guinea pigs. Vaccine 25:7620-7628.
58. Post DM, Ketterer MR, Phillips NJ, Gibson BW, Apicella MA. 2003. The msbB mutant of Neisseria meningitidis strain NMB has a defect in lipooligosaccharide assembly and transport to the outer membrane. Infect. Immun. 71:647-655.
59. Hajjar AM, Ernst RK, Tsai JH, Wilson CB, Miller SI. 2002. Human Toll-like receptor 4 recognizes host-specific LPS modifications. Nat. Immunol. 3:354-359.
60. Kalupahana R, Emilianus AR, Maskell D, Blacklaws B. 2003. Salmonella enterica serovar Typhimurium expressing mutant lipid A with decreased endotoxicity causes maturation of murine dendritic cells. Infect. Immun. 71:6132-6140.
61. Galindo CL, Sha J, Moen ST, Agar SL, Kirtley ML, Foltz SM, McIver LJ, Kozlova EV, Garner HR, Chopra AK. 2010. Comparative global gene expression profiles of wild-type Yersinia pestis CO92 and its Braun lipoprotein mutant at flea and human body temperatures. Comp. Funct. Genomics 2010:342168. doi:10.1155/2010/342168.
62. Li B, Yang R. 2008. Interaction between Yersinia pestis and the host immune system. Infect. Immun. 76:1804-1811.
63. Feodorova VA, Golova AB. 2005. Antigenic and phenotypic modifications of Yersinia pestis under calcium and glucose concentrations simulating the mammalian bloodstream environment. J. Med. Microbiol. 54: 435-441.
64. Murray SR, Bermudes D, de Felipe KS, Low KB. 2001. Extragenic suppressors of growth defects in msbB Salmonella. J. Bacteriol. 183:5554-5561.